Top

Current Oncology Reports

Published in:

01-08-2021 | Naproxen | Immuno-oncology (RM Bukowski and JH Finke, Section Editors)

Immunology of Lynch Syndrome

Authors: Danielle M. Pastor, Jeffrey Schlom

Published in: Current Oncology Reports | Issue 8/2021

Abstract

Purpose of Review

Patients with Lynch syndrome have a high probability of developing colorectal and other carcinomas. This review provides a comprehensive assessment of the immunologic aspects of Lynch syndrome pathogenesis and provides an overview of potential immune interventions for patients with Lynch syndrome polyps and Lynch syndrome–associated carcinomas.

Recent Findings

Immunogenic properties of the majority of Lynch syndrome polyps and associated cancers include microsatellite instability leading to a high mutational burden and the development of novel frameshift peptides, i.e., neoantigens. In addition, patients with Lynch syndrome develop T cell responses in the periphery and in the tumor microenvironment (TME) to tumor-associated antigens, and a proinflammatory cytokine TME has also been identified. However, Lynch syndrome lesions also possess immunosuppressive entities such as alterations in MHC class I antigen presentation, TGFβ receptor mutations, regulatory T cells, and upregulation of PD-L1 on tumor-associated lymphocytes.

Summary

The rich immune microenvironment of Lynch syndrome polyps and associated carcinomas provides an opportunity to employ the spectrum of immune-mediating agents now available to induce and enhance host immune responses and/or to also reduce immunosuppressive entities. These agents can be employed in the so-called prevention trials for the treatment of patients with Lynch syndrome polyps and for trials in patients with Lynch syndrome–associated cancers.

Le DT, Kim TW, Van Cutsem E, Geva R, Jager D, Hara H, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: Keynote-164. J Clin Oncol. 2020;38(1):11–9. https://doi.org/10.1200/JCO.19.02107.CrossRefPubMed

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. https://doi.org/10.1056/NEJMoa1500596.CrossRefPubMedPubMedCentral

3.••

Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–9. https://doi.org/10.1200/JCO.2017.76.9901. Prior studies have shown Lynch syndrome tumors possess mismatch repair deficiency (MSI). The clinical study reported here demonstrated that checkpoint inhibitor MAbs elicit durable clinical benefit in CRC patients who are MSI and thus Lynch syndrome patients may also benefit from such therapy.

Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91. https://doi.org/10.1016/S1470-2045(17)30422-9.CrossRefPubMedPubMedCentral

Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomark Prev. 2017;26(3):404–12. https://doi.org/10.1158/1055-9965.EPI-16-0693.CrossRef

Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26(35):5783–8. https://doi.org/10.1200/JCO.2008.17.5950.CrossRefPubMedPubMedCentral

Vasen HF. Clinical description of the Lynch syndrome [hereditary nonpolyposis colorectal cancer (HNPCC)]. Familial Cancer. 2005;4(3):219–25. https://doi.org/10.1007/s10689-004-3906-5.CrossRefPubMed

Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851–60. https://doi.org/10.1056/NEJMoa043146.CrossRefPubMed

Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, Green JS, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res. 1994;54(7):1645–8.PubMed

10.

Loukola A, Eklin K, Laiho P, Salovaara R, Kristo P, Jarvinen H, et al. Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res. 2001;61(11):4545–9.PubMed

11.

Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999;116(6):1453–6. https://doi.org/10.1016/s0016-5085(99)70510-x.CrossRefPubMed

12.

Buttin BM, Powell MA, Mutch DG, Rader JS, Herzog TJ, Gibb RK, et al. Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res. 2004;10(2):481–90. https://doi.org/10.1158/1078-0432.ccr-1110-03.CrossRefPubMed

13.

Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995;64(6):430–3. https://doi.org/10.1002/ijc.2910640613.CrossRefPubMed

14.

Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst. 2012;104(18):1363–72. https://doi.org/10.1093/jnci/djs351.CrossRefPubMedPubMedCentral

15.

Rijcken FE, Hollema H, Kleibeuker JH. Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut. 2002;50(3):382–6. https://doi.org/10.1136/gut.50.3.382.CrossRefPubMedPubMedCentral

16.

Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006;296(12):1507–17. https://doi.org/10.1001/jama.296.12.1507.CrossRefPubMed

17.

Mecklin JP, Sipponen P, Jarvinen HJ. Histopathology of colorectal carcinomas and adenomas in cancer family syndrome. Dis Colon Rectum. 1986;29(12):849–53. https://doi.org/10.1007/BF02555362.CrossRefPubMed

18.

Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology. 1993;104(5):1535–49. https://doi.org/10.1016/0016-5085(93)90368-m.CrossRefPubMed

19.

Kouri M, Laasonen A, Mecklin JP, Jarvinen H, Franssila K, Pyrhonen S. Diploid predominance in hereditary nonpolyposis colorectal carcinoma evaluated by flow cytometry. Cancer. 1990;65(8):1825–9. https://doi.org/10.1002/1097-0142(19900415)65:8<1825::aid-cncr2820650827>3.0.co;2-h.CrossRefPubMed

20.

Rubenstein JH, Enns R, Heidelbaugh J, Barkun A, Clinical GC. American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch Syndrome. Gastroenterology. 2015;149(3):777–82; quiz e16-7. https://doi.org/10.1053/j.gastro.2015.07.036.CrossRefPubMed

21.

Ladabaum U, Ford JM, Martel M, Barkun AN. American Gastroenterological Association Technical Review on the Diagnosis and Management of Lynch Syndrome. Gastroenterology. 2015;149(3):783–813 e20. https://doi.org/10.1053/j.gastro.2015.07.037.CrossRefPubMed

22.

Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34(5):424–5. https://doi.org/10.1007/BF02053699.CrossRefPubMed

23.

Newton K, Green K, Lalloo F, Evans DG, Hill J. Colonoscopy screening compliance and outcomes in patients with Lynch syndrome. Color Dis. 2015;17(1):38–46. https://doi.org/10.1111/codi.12778.CrossRef

24.

Jass JR. Hereditary non-polyposis colorectal cancer: the rise and fall of a confusing term. World J Gastroenterol. 2006;12(31):4943–50. https://doi.org/10.3748/wjg.v12.i31.4943.CrossRefPubMedPubMedCentral

25.

Kravochuck SE, Kalady MF, Burke CA, Heald B, Church JM. Defining HNPCC and Lynch syndrome: what’s in a name? Gut. 2014;63(9):1525–6. https://doi.org/10.1136/gutjnl-2014-307344.CrossRefPubMed

26.

Drescher KM, Sharma P, Lynch HT. Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch syndrome patients. Clin Dev Immunol. 2010;2010:170432. https://doi.org/10.1155/2010/170432.CrossRefPubMedPubMedCentral

27.

Zetner DB, Bisgaard ML. Familial colorectal cancer type X. Curr Genomics. 2017;18(4):341–59. https://doi.org/10.2174/1389202918666170307161643.CrossRefPubMedPubMedCentral

28.

Mueller-Koch Y, Vogelsang H, Kopp R, Lohse P, Keller G, Aust D, et al. Hereditary non-polyposis colorectal cancer: clinical and molecular evidence for a new entity of hereditary colorectal cancer. Gut. 2005;54(12):1733–40. https://doi.org/10.1136/gut.2004.060905.CrossRefPubMedPubMedCentral

29.

Lynch HT, Lanspa S, Smyrk T, Boman B, Watson P, Lynch J. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I & II). Genetics, pathology, natural history, and cancer control, Part I. Cancer Genet Cytogenet. 1991;53(2):143–60. https://doi.org/10.1016/0165-4608(91)90093-a.CrossRefPubMed

30.

Carethers JM, Stoffel EM. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J Gastroenterol. 2015;21(31):9253–61. https://doi.org/10.3748/wjg.v21.i31.9253.CrossRefPubMedPubMedCentral

31.

Silva FC, Valentin MD, Ferreira Fde O, Carraro DM, Rossi BM. Mismatch repair genes in Lynch syndrome: a review. Sao Paulo Med J. 2009;127(1):46–51. https://doi.org/10.1590/s1516-31802009000100010.CrossRefPubMed

32.

Rumilla K, Schowalter KV, Lindor NM, Thomas BC, Mensink KA, Gallinger S, et al. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn. 2011;13(1):93–9. https://doi.org/10.1016/j.jmoldx.2010.11.011.CrossRefPubMedPubMedCentral

33.

Cini G, Carnevali I, Quaia M, Chiaravalli AM, Sala P, Giacomini E, et al. Concomitant mutation and epimutation of the MLH1 gene in a Lynch syndrome family. Carcinogenesis. 2015;36(4):452–8. https://doi.org/10.1093/carcin/bgv015.CrossRefPubMed

34.

Niessen RC, Hofstra RM, Westers H, Ligtenberg MJ, Kooi K, Jager PO, et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosom Cancer. 2009;48(8):737–44. https://doi.org/10.1002/gcc.20678.CrossRefPubMed

35.

Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res. 2012;18(6):1506–12. https://doi.org/10.1158/1078-0432.Ccr-11-1469.CrossRefPubMedPubMedCentral

36.

Lynch HT, Drescher KM, de la Chapelle A. Immunology and the Lynch syndrome. Gastroenterology. 2008;134(4):1246–9. https://doi.org/10.1053/j.gastro.2008.02.008.CrossRefPubMed

37.

Kloor M, von Knebel Doeberitz M. The immune biology of microsatellite-unstable cancer. Trends Cancer. 2016;2(3):121–33. https://doi.org/10.1016/j.trecan.2016.02.004.CrossRefPubMed

38.

Buckowitz A, Knaebel HP, Benner A, Blaker H, Gebert J, Kienle P, et al. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer. 2005;92(9):1746–53. https://doi.org/10.1038/sj.bjc.6602534.CrossRefPubMedPubMedCentral

39.

Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol. 1999;154(6):1805–13. https://doi.org/10.1016/S0002-9440(10)65436-3.CrossRefPubMedPubMedCentral

40.

Reuschenbach M, Kloor M, Morak M, Wentzensen N, Germann A, Garbe Y, et al. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome. Fam Cancer. 2010;9(2):173–9. https://doi.org/10.1007/s10689-009-9307-z.CrossRefPubMedPubMedCentral

41.

Peltomaki P. Update on Lynch syndrome genomics. Familial Cancer. 2016;15(3):385–93. https://doi.org/10.1007/s10689-016-9882-8.CrossRefPubMedPubMedCentral

42.

Kloor M, Michel S, von Knebel Doeberitz M. Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer. 2010;127(5):1001–10. https://doi.org/10.1002/ijc.25283.CrossRefPubMed

43.

Ishikawa T, Fujita T, Suzuki Y, Okabe S, Yuasa Y, Iwai T, et al. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res. 2003;63(17):5564–72.PubMed

44.

Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology. 2008;134(4):988–97. https://doi.org/10.1053/j.gastro.2008.01.015.CrossRefPubMed

45.

Sinicrope FA. Lynch syndrome-associated colorectal cancer. N Engl J Med. 2018;379(8):764–73. https://doi.org/10.1056/NEJMcp1714533.CrossRefPubMed

46.••

Kloor M, Reuschenbach M, Pauligk C, Karbach J, Rafiyan MR, Al-Batran SE, et al. A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers: a phase I/IIa clinical trial. Clin Cancer Res. 2020;26(17):4503–10. https://doi.org/10.1158/1078-0432.CCR-19-3517. Lynch syndrome tumors possess frameshift peptides (FSPs) as a result of microsatellite instability. This clinical study demonstrated that a vaccine directed against an FSP was well tolerated and elicited both antibody and T-cell responses.

47.

Bauer K, Nelius N, Reuschenbach M, Koch M, Weitz J, Steinert G, et al. T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer. Cancer Immunol Immunother. 2013;62(1):27–37. https://doi.org/10.1007/s00262-012-1303-8.CrossRefPubMed

48.

von Knebel DM, Kloor M. Towards a vaccine to prevent cancer in Lynch syndrome patients. Familial Cancer. 2013;12(2):307–12. https://doi.org/10.1007/s10689-013-9662-7.CrossRef

49.

Ballhausen A, Przybilla MJ, Jendrusch M, Haupt S, Pfaffendorf E, Draxlbauer M, et al. The shared neoantigen landscape of MSI cancers reflects immunoediting during tumor evolution. bioRxiv. 2019:691469. https://doi.org/10.1101/691469.

50.

Woerner SM, Kloor M, von Knebel DM, Gebert JF. Microsatellite instability in the development of DNA mismatch repair deficient tumors. Cancer Biomark. 2006;2(1-2):69–86. https://doi.org/10.3233/cbm-2006-21-208.CrossRefPubMed

51.

Woerner SM, Tosti E, Yuan YP, Kloor M, Bork P, Edelmann W, et al. Detection of coding microsatellite frameshift mutations in DNA mismatch repair-deficient mouse intestinal tumors. Mol Carcinog. 2015;54(11):1376–86. https://doi.org/10.1002/mc.22213.CrossRefPubMed

52.

Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, et al. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer. 2001;93(1):6–11. https://doi.org/10.1002/ijc.1298.CrossRefPubMed

53.

Saeterdal I, Bjorheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A. 2001;98(23):13255–60. https://doi.org/10.1073/pnas.231326898.CrossRefPubMedPubMedCentral

54.

Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995;268(5215):1336–8. https://doi.org/10.1126/science.7761852.CrossRefPubMed

55.

Ripberger E, Linnebacher M, Schwitalle Y, Gebert J, von Knebel Doeberitz M. Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunol. 2003;23(5):415–23. https://doi.org/10.1023/a:1025329819121.CrossRefPubMed

56.

Akiyama Y, Iwanaga R, Saitoh K, Shiba K, Ushio K, Ikeda E, et al. Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer. Gastroenterology. 1997;112(1):33–9. https://doi.org/10.1016/s0016-5085(97)70216-6.CrossRefPubMed

57.

Lebrun JJ. The dual role of TGFβ in human cancer: from tumor suppression to cancer metastasis. ISRN Mol Biol. 2012;2012:381428. https://doi.org/10.5402/2012/381428.CrossRefPubMedPubMedCentral

58.

Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, et al. TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst. 2014;106(2):djt369. https://doi.org/10.1093/jnci/djt369.CrossRefPubMedPubMedCentral

59.

David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J, Palena C. A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunology. 2017;6(10):e1349589. https://doi.org/10.1080/2162402x.2017.1349589.CrossRefPubMedPubMedCentral

60.

Grenga I, Donahue RN, Gargulak ML, Lepone LM, Roselli M, Bilusic M, et al. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. Urol Oncol. 2018;36(3):93.e1–e11. https://doi.org/10.1016/j.urolonc.2017.09.027.CrossRef

61.

Knudson KM, Hicks KC, Luo X, Chen JQ, Schlom J, Gameiro SR. M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. Oncoimmunology. 2018;7(5):e1426519. https://doi.org/10.1080/2162402x.2018.1426519.CrossRefPubMedPubMedCentral

62.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–8. https://doi.org/10.1038/ni1102-991.CrossRefPubMed

63.

Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25. https://doi.org/10.1016/j.coi.2014.01.004.CrossRefPubMedPubMedCentral

64.

Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet. 2005;42(6):491–6. https://doi.org/10.1136/jmg.2004.024299.CrossRefPubMedPubMedCentral

65.

Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012;10:205. https://doi.org/10.1186/1479-5876-10-205.CrossRefPubMedPubMedCentral

66.••

Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, et al. Immune profiling of premalignant lesions in patients with Lynch syndrome. JAMA Oncol. 2018;4(8):1085–92. https://doi.org/10.1001/jamaoncol.2018.1482. This study demonstrated that Lynch syndrome premalignant lesions possessed T-cell infiltration and a proinflammatory phenotype, both of which may make these lesions appropriate for immune therapeutic interventions.

67.

Koornstra JJ, de Jong S, Boersma-van Eck W, Zwart N, Hollema H, de Vries EG, et al. Fas ligand expression in lynch syndrome-associated colorectal tumours. Pathol Oncol Res. 2009;15(3):399–406. https://doi.org/10.1007/s12253-008-9136-7.CrossRefPubMed

68.

Huard B, Tournier M, Hercend T, Triebel F, Faure F. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur J Immunol. 1994;24(12):3216–21. https://doi.org/10.1002/eji.1830241246.CrossRefPubMed

69.

Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503–13. https://doi.org/10.1016/j.immuni.2004.08.010.CrossRefPubMed

70.

Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest. 2007;117(11):3383–92. https://doi.org/10.1172/JCI31184.CrossRefPubMedPubMedCentral

71.

Woerner SM, Kloor M, Mueller A, Rueschoff J, Friedrichs N, Buettner R, et al. Microsatellite instability of selective target genes in HNPCC-associated colon adenomas. Oncogene. 2005;24(15):2525–35. https://doi.org/10.1038/sj.onc.1208456.CrossRefPubMed

72.

de Miranda NF, Goudkade D, Jordanova ES, Tops CM, Hes FJ, Vasen HF, et al. Infiltration of Lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases. Clin Cancer Res. 2012;18(5):1237–45. https://doi.org/10.1158/1078-0432.CCR-11-1997.CrossRefPubMed

73.

Watson P, Lin KM, Rodriguez-Bigas MA, Smyrk T, Lemon S, Shashidharan M, et al. Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer. 1998;83(2):259–66.CrossRef

74.

Willis JA, Reyes-Uribe L, Chang K, Lipkin SM, Vilar E. Immune activation in mismatch repair-deficient carcinogenesis: more than just mutational rate. Clin Cancer Res. 2020;26(1):11–7. https://doi.org/10.1158/1078-0432.Ccr-18-0856.CrossRefPubMed

75.

Echterdiek F, Janikovits J, Staffa L, Muller M, Lahrmann B, Fruhschutz M, et al. Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. Oncoimmunology. 2016;5(2):e1075692. https://doi.org/10.1080/2162402X.2015.1075692.CrossRefPubMed

76.

Walkowska J, Kallemose T, Jonsson G, Jonsson M, Andersen O, Andersen MH, et al. Immunoprofiles of colorectal cancer from Lynch syndrome. Oncoimmunology. 2018;8(1):e1515612. https://doi.org/10.1080/2162402X.2018.1515612.CrossRefPubMedPubMedCentral

77.

Kloor M, Michel S, Buckowitz B, Ruschoff J, Buttner R, Holinski-Feder E, et al. Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer. 2007;121(2):454–8. https://doi.org/10.1002/ijc.22691.CrossRefPubMed

78.

Dierssen JW, de Miranda NF, Ferrone S, van Puijenbroek M, Cornelisse CJ, Fleuren GJ, et al. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. BMC Cancer. 2007;7:33. https://doi.org/10.1186/1471-2407-7-33.CrossRefPubMedPubMedCentral

79.

Cerretelli G, Ager A, Arends MJ, Frayling IM. Molecular pathology of Lynch syndrome. J Pathol. 2020;250(5):518–31. https://doi.org/10.1002/path.5422.CrossRefPubMed

80.

Janikovits J, Muller M, Krzykalla J, Korner S, Echterdiek F, Lahrmann B, et al. High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer. Oncoimmunology. 2018;7(2):e1390640. https://doi.org/10.1080/2162402X.2017.1390640.CrossRefPubMed

81.

Koelzer VH, Baker K, Kassahn D, Baumhoer D, Zlobec I. Prognostic impact of beta-2-microglobulin expression in colorectal cancers stratified by mismatch repair status. J Clin Pathol. 2012;65(11):996–1002. https://doi.org/10.1136/jclinpath-2012-200742.CrossRefPubMed

82.

Bernal M, Ruiz-Cabello F, Concha A, Paschen A, Garrido F. Implication of the beta2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol Immunother. 2012;61(9):1359–71. https://doi.org/10.1007/s00262-012-1321-6.CrossRefPubMed

83.

Bicknell DC, Kaklamanis L, Hampson R, Bodmer WF, Karran P. Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas. Curr Biol. 1996;6(12):1695–7. https://doi.org/10.1016/s0960-9822(02)70795-1.CrossRefPubMed

84.

Shiraliyeva N, Friedrichs J, Buettner R, Friedrichs N. PD-L1 expression in HNPCC-associated colorectal cancer. Pathol Res Pract. 2017;213(12):1552–5. https://doi.org/10.1016/j.prp.2017.09.012.CrossRefPubMed

85.

Kim JH, Park HE, Cho NY, Lee HS, Kang GH. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers. Br J Cancer. 2016;115(4):490–6. https://doi.org/10.1038/bjc.2016.211.CrossRefPubMedPubMedCentral

86.

Burn J, Bishop DT, Mecklin JP, Macrae F, Moslein G, Olschwang S, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008;359(24):2567–78. https://doi.org/10.1056/NEJMoa0801297.CrossRefPubMed

87.

Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081–7. https://doi.org/10.1016/S0140-6736(11)61049-0.CrossRefPubMedPubMedCentral

88.

Burn J, Sheth H, Elliott F, Reed L, Macrae F, Mecklin JP, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020;395(10240):1855–63. https://doi.org/10.1016/S0140-6736(20)30366-4.CrossRefPubMedPubMedCentral

89.

Movahedi M, Bishop DT, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: a prospective investigation in the CAPP2 study. J Clin Oncol. 2015;33(31):3591–7. https://doi.org/10.1200/JCO.2014.58.9952.CrossRefPubMed

90.

Ait Ouakrim D, Dashti SG, Chau R, Buchanan DD, Clendenning M, Rosty C, et al. Aspirin, ibuprofen, and the risk of colorectal cancer in Lynch Syndrome. J Natl Cancer Inst. 2015;107(9). https://doi.org/10.1093/jnci/djv170.

91.

Reyes-Uribe L, Wu W, Gelincik O, Bommi PV, Francisco-Cruz A, Solis LM, et al. Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. Gut. 2021;70(3):555–66. https://doi.org/10.1136/gutjnl-2020-320946.

92.

Kucherlapati MH, Lee K, Nguyen AA, Clark AB, Hou H Jr, Rosulek A, et al. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology. 2010;138(3):993–1002 e1. https://doi.org/10.1053/j.gastro.2009.11.009.CrossRefPubMed

93.

McIlhatton MA, Tyler J, Kerepesi LA, Bocker-Edmonston T, Kucherlapati MH, Edelmann W, et al. Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model. Cancer Prev Res (Phila). 2011;4(5):684–93. https://doi.org/10.1158/1940-6207.CAPR-10-0319.CrossRef

94.

Martin-Lopez J, Gasparini P, Coombes K, Croce CM, Boivin GP, Fishel R. Mutation of TGFbeta-RII eliminates NSAID cancer chemoprevention. Oncotarget. 2018;9(16):12554–61. https://doi.org/10.18632/oncotarget.23792.CrossRefPubMed

95.

Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015;16(1):64. https://doi.org/10.1186/s13059-015-0620-6.CrossRefPubMedPubMedCentral

96.

Angelova M, Charoentong P, Hackl H, Trajanoski Z. The colorectal cancer immune paradox revisited. Oncoimmunology. 2016;5(2):e1078058. https://doi.org/10.1080/2162402x.2015.1078058.CrossRefPubMed

97.

Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 2009;45(10):1890–6. https://doi.org/10.1016/j.ejca.2009.04.018.CrossRefPubMed

98.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4. https://doi.org/10.1126/science.1129139.CrossRefPubMed

99.

Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, Tejpar S. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann Oncol. 2015;26(1):126–32. https://doi.org/10.1093/annonc/mdu499.CrossRefPubMed

100.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13. https://doi.org/10.1126/science.aan6733.CrossRefPubMedPubMedCentral

101.

Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, et al. A blueprint to advance colorectal cancer immunotherapies. Cancer Immunol Res. 2017;5(11):942–9. https://doi.org/10.1158/2326-6066.Cir-17-0375.CrossRefPubMed

102.

Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247–57. https://doi.org/10.1056/NEJMoa022289.CrossRefPubMedPubMedCentral

103.

Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26. https://doi.org/10.1200/jco.2009.27.1825.CrossRefPubMedPubMedCentral

104.

Shulman K, Barnett-Griness O, Friedman V, Greenson JK, Gruber SB, Lejbkowicz F, et al. Outcomes of chemotherapy for microsatellite instable-high metastatic colorectal cancers. JCO Precis Oncol. 2018;2. https://doi.org/10.1200/po.17.00253.

105.

Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 2010;7(3):153–62. https://doi.org/10.1038/nrclinonc.2009.237.CrossRefPubMedPubMedCentral

106.

Dominguez-Valentin M, Seppala TT, Sampson JR, Macrae F, Winship I, Evans DG, et al. Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report. Hered Cancer Clin Pract. 2019;17:28. https://doi.org/10.1186/s13053-019-0127-3.CrossRefPubMedPubMedCentral

107.

Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100(2):266–73. https://doi.org/10.1038/sj.bjc.6604867.CrossRefPubMedPubMedCentral

108.

Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20(20):5322–30. https://doi.org/10.1158/1078-0432.Ccr-14-0332.CrossRefPubMedPubMedCentral

109.

Benatti P, Gafà R, Barana D, Marino M, Scarselli A, Pedroni M, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res. 2005;11(23):8332–40. https://doi.org/10.1158/1078-0432.Ccr-05-1030.CrossRefPubMed

110.

Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009;27(11):1814–21. https://doi.org/10.1200/jco.2008.18.2071.CrossRefPubMedPubMedCentral

111.

Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 2000;355(9217):1745–50. https://doi.org/10.1016/S0140-6736(00)02261-3.CrossRefPubMed

112.

Fallik D, Borrini F, Boige V, Viguier J, Jacob S, Miquel C, et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 2003;63(18):5738–44.PubMed

113.

Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol. 2007;25(7):767–72. https://doi.org/10.1200/JCO.2006.05.8172.CrossRefPubMed

114.

Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609–18. https://doi.org/10.1200/JCO.2005.01.086.CrossRefPubMed

115.

de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, Griffioen G, et al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer. 2004;109(3):468–71. https://doi.org/10.1002/ijc.11712.CrossRefPubMed

116.

FDA press release: “FDA approves pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer”: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer. (2020). Accessed 11.30.20.

117.

Andre T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt CJA, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 study. Abstract. ASCO Annual Meeting. J Clin Oncol. 2020;38(18_suppl):LBA4–LBA. https://doi.org/10.1200/JCO.2020.38.18_suppl.LBA4.CrossRef

118.

Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018;6(1):35. https://doi.org/10.1186/s40425-018-0342-x.CrossRefPubMedPubMedCentral

119.

Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med. 2017;377(15):1409–12. https://doi.org/10.1056/NEJMp1709968.CrossRef

120.

FDA press release: “FDA grants nivolumab accelerated approval for MSI-H or dMMR colorectal cancer”: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-nivolumab-accelerated-approval-msi-h-or-dmmr-colorectal-cancer. (2020). Accessed 11/30/20.

121.

FDA press release: “FDA grants accelerated approval to ipilimumab for MSI-H or dMMR metastatic colorectal cancer”: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-ipilimumab-msi-h-or-dmmr-metastatic-colorectal-cancer. (2020). Accessed 11/30/20.

122.

Ghatalia P, Nagarathinam R, Cooper H, Geynisman DM, El-Deiry WS. Mismatch repair deficient metastatic colon cancer and urothelial cancer: a case report of sequential immune checkpoint therapy. Cancer Biol Ther. 2017;18(9):651–4. https://doi.org/10.1080/15384047.2017.1356506.CrossRefPubMedPubMedCentral

123.

Musher B, Rahal A. Single-agent immunotherapy for two types of cancer in one patient. Ann Intern Med. 2019;170(3):210–1. https://doi.org/10.7326/l18-0360.CrossRefPubMed

124.

Winer A, Ghatalia P, Bubes N, Anari F, Varshavsky A, Kasireddy V, et al. Dual checkpoint inhibition with ipilimumab plus nivolumab after progression on sequential PD-1/PDL-1 inhibitors pembrolizumab and atezolizumab in a patient with lynch syndrome, metastatic colon, and localized urothelial cancer. Oncologist. 2019;24(11):1416–9. https://doi.org/10.1634/theoncologist.2018-0686.CrossRefPubMedPubMedCentral

125.

Bari S, Kim RD, Wang X, Matejcic M, Muzaffar J. Outcomes of Lynch syndrome (LS) patients treated with immune checkpoint inhibitors (ICI). J Clin Oncol. 2020;38(15_suppl):1548. https://doi.org/10.1200/JCO.2020.38.15_suppl.1548.CrossRef

126.

Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol. 2002;20(8):2197–207. https://doi.org/10.1200/JCO.2002.08.017.CrossRefPubMed

127.

Engel BJ, Bowser JL, Broaddus RR, Carson DD. MUC1 stimulates EGFR expression and function in endometrial cancer. Oncotarget. 2016;7(22):32796–809. https://doi.org/10.18632/oncotarget.8743.CrossRefPubMedPubMedCentral

128.

Finn OJ. Human tumor antigens yesterday, today, and tomorrow. Cancer Immunol Res. 2017;5(5):347–54. https://doi.org/10.1158/2326-6066.CIR-17-0112.CrossRefPubMedPubMedCentral

129.••

Finn OJ. The dawn of vaccines for cancer prevention. Nat Rev Immunol. 2018;18(3):183–94. https://doi.org/10.1038/nri.2017.140. This article describes the different types of tumor-associated shared antigens and unique neoantigens found in Lynch syndrome‒associated cancers and thus supports potential immunotherapeutic approaches for Lynch syndrome polyps and associated cancers.

130.

Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008;6(B):955–64.PubMedPubMedCentral

131.

Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother. 2005;54(3):254–64. https://doi.org/10.1007/s00262-004-0581-1.CrossRefPubMed

132.

Balint JP, Gabitzsch ES, Rice A, Latchman Y, Xu Y, Messerschmidt GL, et al. Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. Cancer Immunol Immunother. 2015;64(8):977–87. https://doi.org/10.1007/s00262-015-1706-4.CrossRefPubMedPubMedCentral

133.

Gatti-Mays ME, Redman JM, Donahue RN, Palena C, Madan RA, Karzai F, et al. A phase I trial using a multitargeted recombinant adenovirus 5 (CEA/MUC1/brachyury)-based immunotherapy vaccine regimen in patients with advanced cancer. Oncologist. 2020;25(6):479–e899. https://doi.org/10.1634/theoncologist.2019-0608.CrossRefPubMed

134.

Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila). 2013;6(1):18–26. https://doi.org/10.1158/1940-6207.CAPR-12-0275.CrossRef

135.

Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM, et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother. 2013;62(8):1293–301. https://doi.org/10.1007/s00262-013-1400-3.CrossRefPubMedPubMedCentral

136.

Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Beatty PL, Kastenberg D, et al. Abstract LB-305: Randomized, double-blind, placebo-controlled immunoprevention trial with MUC1 vaccine in patients with newly diagnosed advanced adenomas. Cancer Res. 2018;78(13 Supplement):LB-305–LB. https://doi.org/10.1158/1538-7445.Am2018-lb-305.CrossRef

137.

Gelincik O, Ibrahim H, Ozkan M, Ahadova A, Sei S, Shoemaker R, et al. Abstract 2732: Frameshift neoantigen vaccination prevent Lynch syndrome mouse model intestinal cancer. 2019 AACR Annual Meeting, Atlanta, GA. Cancer Res. 2019;79(13 Suppl):2732. https://doi.org/10.1158/1538-7445.AM2019-2732.

138.

Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res. 2002;62(23):6944–51.PubMed

139.

Zeytin HE, Patel AC, Rogers CJ, Canter D, Hursting SD, Schlom J, et al. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res. 2004;64(10):3668–78. https://doi.org/10.1158/0008-5472.Can-03-3878.CrossRefPubMed

140.

Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018;19(5):694–704. https://doi.org/10.1016/s1470-2045(18)30148-7.CrossRefPubMedPubMedCentral

141.

Schlom J, Gulley JL. Vaccines as an integral component of cancer immunotherapy. Jama. 2018;320(21):2195–6. https://doi.org/10.1001/jama.2018.9511.CrossRefPubMedPubMedCentral

142.

Jezkova J, Williams JS, Pinto F, Sammut SJ, Williams GT, Gollins S, et al. Brachyury identifies a class of enteroendocrine cells in normal human intestinal crypts and colorectal cancer. Oncotarget. 2016;7(10):11478–86. https://doi.org/10.18632/oncotarget.7202.CrossRefPubMedPubMedCentral

143.

Kilic N, Feldhaus S, Kilic E, Tennstedt P, Wicklein D, Wasielewski R, et al. Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer. 2011;47(7):1080–5. https://doi.org/10.1016/j.ejca.2010.11.015.CrossRefPubMed

144.

Palena C, Fernando RI, Litzinger MT, Hamilton DH, Huang B, Schlom J. Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells. Exp Biol Med (Maywood). 2011;236(5):537–45. https://doi.org/10.1258/ebm.2011.010367.CrossRef

145.

Sarkar D, Shields B, Davies ML, Müller J, Wakeman JA. BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells. Int J Cancer. 2012;130(2):328–37. https://doi.org/10.1002/ijc.26029.CrossRefPubMed

146.

Collins JM, Donahue RN, Tsai YT, Manu M, Palena C, Gatti-Mays ME, et al. Phase I trial of a modified vaccinia Ankara priming vaccine followed by a fowlpox virus boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors. Oncologist. 2020;25(7):560–e1006. https://doi.org/10.1634/theoncologist.2019-0932.CrossRefPubMed

147.

Gatti-Mays ME, Strauss J, Donahue RN, Palena C, Del Rivero J, Redman JM, et al. A phase I dose-escalation trial of BN-CV301, a recombinant poxviral vaccine targeting MUC1 and CEA with costimulatory molecules. Clin Cancer Res. 2019;25(16):4933–44. https://doi.org/10.1158/1078-0432.Ccr-19-0183.CrossRefPubMedPubMedCentral

148.

Finn OJ, Beatty PL. Cancer immunoprevention. Curr Opin Immunol. 2016;39:52–8. https://doi.org/10.1016/j.coi.2016.01.002.CrossRefPubMedPubMedCentral

149.

Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5(1):67–73. https://doi.org/10.1001/jamaoncol.2018.4051.CrossRefPubMed

150.

Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, et al. A first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors. Clin Cancer Res. 2018;24(7):1525–35. https://doi.org/10.1158/1078-0432.Ccr-17-2451.CrossRefPubMed

151.

Kim PS, Kwilas AR, Xu W, Alter S, Jeng EK, Wong HC, et al. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget. 2016;7(13):16130–45. https://doi.org/10.18632/oncotarget.7470.CrossRefPubMedPubMedCentral

152.

Horn LA, Riskin J, Hempel HA, Fousek K, Lind H, Hamilton DH, et al. Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity. J Immunother Cancer. 2020;8(1). https://doi.org/10.1136/jitc-2019-000326.

153.

Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JM, et al. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances. J Immunother Cancer. 2020;8(1). https://doi.org/10.1136/jitc-2019-000433.

154.

Morillon YM 2nd, Su Z, Schlom J, Greiner JW. Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12. J Immunother Cancer. 2019;7(1):150. https://doi.org/10.1186/s40425-019-0620-2.CrossRefPubMedPubMedCentral

155.

Morillon YMI, Smalley Rumfield C, Pellom ST, Sabzevari A, Roller NT, Horn LA, et al. The use of a humanized NSG-β2m(-/-) model for investigation of immune and anti-tumor effects mediated by the bifunctional immunotherapeutic bintrafusp alfa. Front Oncol. 2020;10:549. https://doi.org/10.3389/fonc.2020.00549.CrossRefPubMedPubMedCentral

156.

Hicks KC, Fantini M, Donahue RN, Schwab A, Knudson KM, Tritsch SR, et al. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. Oncoimmunology. 2018;7(11):e1466018. https://doi.org/10.1080/2162402x.2018.1466018.CrossRefPubMedPubMedCentral

157.

Hicks KC, Knudson KM, Lee KL, Hamilton DH, Hodge JW, Figg WD, et al. Cooperative immune-mediated mechanisms of the HDAC inhibitor entinostat, an IL15 superagonist, and a cancer vaccine effectively synergize as a novel cancer therapy. Clin Cancer Res. 2020;26(3):704–16. https://doi.org/10.1158/1078-0432.Ccr-19-0727.CrossRefPubMed

158.

Li A, Yi M, Qin S, Chu Q, Luo S, Wu K. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol. 2019;12(1):98. https://doi.org/10.1186/s13045-019-0784-8.CrossRefPubMedPubMedCentral

Title: Immunology of Lynch Syndrome
Authors: Danielle M. Pastor
Jeffrey Schlom
Publication date: 01-08-2021
Publisher: Springer US
Keywords: Naproxen
Colorectal Cancer
Colorectal Cancer
Published in: Current Oncology Reports / Issue 8/2021
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-021-01085-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 8/2021

The Role and Impact of Social Media in Cardio-oncology During the COVID-19 Pandemic

Progress in Gynecologic Cancers with Antibody Drug Conjugates

Prostate Cancer Immunotherapy—Finally in From the Cold?

ROS1 Targeted Therapies: Current Status

Current Approaches to Philadelphia Chromosome–Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant

Navigating the Cancer Screening Decision for Patients with Dementia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer